Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ...

Developing a biosimilar requires years of research and significant capital. In-licensing allows companies to acquire or ...

Alvotech () has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for smart ...

Recently launched biosimilars across markets have begun scaling up and will gather momentum through the year, particularly in ...

CVS Caremark will expand the use of lower-cost biosimilars across multiple therapeutic categories effective July 1.

Viatris is leaving the biosimilar field just months after winning the landmark FDA approval for the first interchangeable biosimilar product. Biocon Biologics, a subsidiary of Biocon, will buy Viatris ...

CVS announced Tuesday it will expand its use of lower-cost biosimilars and tr | The move to prioritize biosimilars comes as ...

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...

U.S. regulators took action Wednesday that should make it easier to get a cheaper near-copy of a brand-name insulin at the drugstore. Doctors must now prescribe what's called a biosimilar drug, or OK ...

The Biologics Price Competition and Innovation Act (BPCIA), part of the 2010 Affordable Care Act, sought to drive down prices for biologics, much as the 1984 Hatch-Waxman Act did for small-molecule ...

CVS Health (NYSE: CVS) today announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including ...